µ¼Ê¦ÐÕÃû£ºÎâÏþÃ÷
ÐÔ±ð£ºÄÐ
ÈËÆøÖ¸Êý£º109
ËùÊôԺУ£ºÖйúÒ©¿Æ´óѧ
ËùÊôԺϵ£ºÒ©Îï¿ÆÑ§Ñо¿Ôº
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£º²©µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÒ©Îﻯѧ
Ñо¿ÁìÓò£º ÌìÈ»²úÎïµÄºÏ³É¡¢ÓÅ»¯ÓëÆÀ¼ÛÑо¿¡£
Ñо¿ÁìÓò£º ÌìÈ»²úÎïµÄºÏ³É¡¢ÓÅ»¯ÓëÆÀ¼ÛÑо¿¡£ [ÊÕÆð]
¸öÈ˼òÊö :
1997Äê--2013ÄêÈÎÖйúÒ©¿Æ´óѧУ³¤¡£¼æÈÎÖйúҩѧ»á¸±Àíʳ¤¡¢ÖйúÒ½Ò©½ÌÓýлḱ»á³¤¡¢½ËÕʡҩѧ»áÃûÓþÀíʳ¤¡¢½ÌÓý²¿Ò©Ñ§öλÔÓéÀֵǼÈë¿ÚÏÂÔØÑ§Î»½Ìѧָµ¼Î¯Ô±»á¸±Ö÷ÈÎίԱ£¬ÖйúѧλÓëÑо¿Éú½ÌÓýѧ»áҩѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØÑ§Î»¹¤×÷ίԱ»áÖ÷ÈÎίԱ£¬Öйú¸ßµÈ½ÌÓýѧ»áҩѧ½ÌÓýÑо¿»áÀíʳ¤£¬µÚÎå½ì½ÌÓý²¿¿ÆÑ§¼¼ÊõίԱ»áѧ²¿Î¯Ô±¡¢µÚÊ®¶þ½ì½ËÕÊ¡ÈË´ó´ú±í¡¢È«¹úҽҩԺУҩѧÀà½Ì²Ä±àί»áÖ÷ÈΡ¢¡¶ÖйúÌìȻҩÎï¡·µÈ¶à¼ÒÒ½Ò©ÔÓÖ¾¡¢ÆÚ¿¯µÄÖ÷±à¡¢¸±Ö÷±à¡¢±àίºÍÌØÑû±àί¡£ÎâÏþÃ÷¿ÎÌâ×éÖ÷Òª´ÓÊ¿¹Ö×Áö¡¢¿¹ÐÄѪ¹Ü¼²²¡Ò©Îï¡¢¿¹ÌÇÄò²¡Ò©ÎïµÄÒ©ÎﻯѧÑо¿£¬ÔÚ²»¶Ô³ÆºÏ³É·´Ó¦µÄ»ù´¡Ñо¿¡¢ÐÂÐÍ·ÇëÄÀàѪ¹Ü½ôÕÅËØ£¨¢ò£©£¨A¢ò£©ÊÜÌåÞ׿¹¼Á¡¢ÐÂÐÍa-ÆÏÌÑÌÇÜÕøÒÖÖÆ¼ÁµÈ¾ßÓÐÉúÀí»îÐÔµÄÌìÈ»²úÎïµÄÈ«ºÏ³É¼°¹¹Ð§¹ØÏµµÈ·½Ãæ½øÐÐÁË´óÁ¿µÄÑо¿¹¤×÷¡£ÏȺóÖ÷³ÖºÍ²Î¼Ó¹ú¼Ò¡°863¡±¼Æ»®¡¢¹ú¼Ò¡°ÐÂÒ©´´ÖÆ¡±¿Æ¼¼ÖØ´óרÏî, ¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÃæÉÏÏîÄ¿µÈ¶àÏî¹ú¼Ò¼°Ê¡²¿¼¶¿ÆÑпÎÌâ¼°¶àÏî¹ú¼ÒÖØµã½Ì¸Ä¿ÎÌ⣬ÔÚ±¾Ñ§¿ÆÖØÒªÔÓÖ¾£ºChem Commun, Org Lett, Eur J Med Chem, BMC, BMCL, Tetrahedron, Tetrahedron LettµÈ¹úÄÚÍâѧÊõ¿¯ÎïÉÏ·¢±íѧÊõÂÛÎÄ200ÓàÆª£¬Á½´Î»ñ¹ú¼Ò¼¶½Ìѧ³É¹ûÒ»µÈ½±£¬Á½´Î»ñ½ËÕÊ¡½Ìѧ³É¹ûÌØµÈ½±£¬»ñ½ËÕÊ¡¿Æ¼¼½ø²½Ò»µÈ½±¡¢¹ã¶«Ê¡¿Æ¼¼½ø²½Ò»µÈ½±£¬¹ú¼ÒÁôѧ»Ø¹úÈËÔ±³É¾Í½±¡¢È«¹úÁôѧ»Ø¹úÈËÔ±ÏȽø¸öÈ˵ȣ¬Îª¹úÎñÔºÕþ¸®ÌØÊâ½òÌùר¼Ò¡£
¿ÆÑй¤×÷ :
½üÆÚ´ú±íÐÔSCIÂÛÎÄ£º1. Renren Bai, Zhen Wei, Jie Liu, Weijia Xie, Hequan Yao, Xiaoming Wu*, Jieyun Jiang, Qiujuan Wang, Jinyi Xu*. Synthesis and biological evaluation of 4¡ä-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists. Bioorganic & Medicinal Chemistry, 2012, 20(15), 4661-4667.2. Dahong Li, Hao Cai, Bowen Jiang, Guyue Liu, Yuetong Wang, Lei Wang, Hequan Yao, Xiaoming Wu*, Yijun Sun, Jinyi Xu*. Synthesis of spirolactone-type diterpenoid derivatives from kaurene-type oridonin with improved antiproliferative effects and their apoptosis-inducing activity in human hepatoma Bel-7402 cells. European Journal of Medicinal Chemistry, 2013, 59, 322-328.3. Ziyuan Li, Ling Ma, JinyiXu, Lingyi Kong, Xiaoming Wu*, Hequan Yao*. Pd(II)-catalyzed direct C5-arylation of azole-4-carboxylates through double C-H bond cleavage. Chemical Communications, 2012, 48(31), 3763-3765.4. Lei Zhao, Ziyuan Li, Lin Chang, JinyiXu, Hequan Yao*, Xiaoming Wu*. Efficient Construction of Fused Indolines with a 2-Quaternary Center via an Intramolecular Heck Reaction with a Low Catalyst Loading. Organic Letters, 2012, 68(14), 2066-2069.5. Renren Bai, Xue Yang, Wen Hong, Yiqun Tang, Shengtao Xu, Hequan Yao, Jieyun Jiang, Jie Liu, Mingqin Shen, Xiaoming Wu*, Jinyi Xu*. Novel hybrids of natural isochroman-4-one bearing N-substituted isopropanolamine as potential antihypertensive candidates. Bioorganic & Medicinal Chemistry, 2013, 21, 2495-2502.6. Dan Liu, Weijia Xie*, Long Liu, Hequan Yao, Jinyi Xu, Genzoh Tanabe, Osamu Muraoka, Xiaoming Wu*. Synthetic study on neoponkoranol and its side chain epimer as potent a-glucosidase inhibitors, optimization of protecting group. Tetrahedron Letters. 2013, 54, 6333-6336.7. Dahong Li, Shengtao Xu, Hao Cai, Lingling Pei, Lei Wang, Hequan Yao, Xiaoming Wu*, Jieyun Jiang, Yijun Sun, Jinyi Xu*. Library construction and biological evaluation of novel enmein-type diterpenoid analogs as potential anticancer agents. Chem. Med. Chem., 2013, 8: 812-818.8. Dahong Li, Shengtao Xu, Hao Cai, Lingling Pei, Hengyuan Zhang, Lei Wang, Hequan Yao, Xiaoming Wu*, Jieyun Jiang, Yijun Sun, Jinyi Xu*. Enmein-type diterpenoid analogs from natural kaurene-type oridonin: synthesis and their antitumor biological evaluation Eur. J. Med. Chem. 2013, 64, 215-221.9. Long Liu, Chengqian Wang, Dan Liu, Weigang He, Jinyi Xu, Aijun Lin, Hequan Yao, Genzoh Tanabe, Osamu Muraoka, Weijia Xie,* Xiaoming Wu,* Construction of 3,6-Anhydrohexosides via Intramolecular Cyclization of Triflates and Its Application to the Synthesis of Natural Product Isolated from Leaves of Sauropus rostratus. Organic Letters 2014, 16, 5004-5007.10. Bo Jiang, Xiaojing Huang, Hequan Yao, Jieyun Jiang, Xiaoming Wu*, Siyi Jiang, Qiujuan Wang, Tao Lu and Jinyi Xu*. Discovery of potential anti-inflammatory drugs: diaryl-1,2,4-triazoles bearing N-hydroxyurea moiety as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase. Org. Biomol. Chem., 2014, 12, 2114-2127.
ÖйúÒ©¿Æ´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÎâÏþÃ÷
±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø/2019-05-27
Ïà¹Ø»°Ìâ/ҩѧ µ¼Ê¦ ÓÅ»¯ Ò©Îﻯѧ Ò½Ò©
ÖØÇì´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÍõÖ÷¶¡
µ¼Ê¦ÐÕÃû£ºÍõÖ÷¶¡ÐÔ±ð£ºÈËÆøÖ¸Êý£º109ËùÊôԺУ£ºÖØÇì´óѧËùÊôԺϵ£ºµçÆø¹¤³ÌѧԺְ³Æ£ºµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÑо¿ÁìÓò£ºµçÍø¹æ»®ÓÅ»¯ÓëÔËÐÐÓÅ»¯Ñо¿ÁìÓò£ºµçÍø¹æ»®ÓÅ»¯ÓëÔËÐÐÓÅ»¯[ÊÕÆð] ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖØÇì´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-³ÂÅà·å
µ¼Ê¦ÐÕÃû£º³ÂÅà·åÐÔ±ð£ºÈËÆøÖ¸Êý£º109ËùÊôԺУ£ºÖØÇì´óѧËùÊôԺϵ£º¹«¹²¹ÜÀíѧԺְ³Æ£ºµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖйúÒ©¿Æ´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-Ç®º£
µ¼Ê¦ÐÕÃû£ºÇ®º£ÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º109ËùÊôԺУ£ºÖйúÒ©¿Æ´óѧËùÊôԺϵ£ºÒ©Ñ§Ôº¡¢Ò©Îï¿ÆÑ§Ñо¿ÔºÖ°³Æ£ºÑо¿Ô±µ¼Ê¦ÀàÐÍ£º²©µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÒ©Îﻯѧ¡¢Ò©Ñ§£¨¹¤ÒµÒ©Ñ§·½Ïò£©Ñо¿ÁìÓò£ºÐÂÒ©·Ö×ÓÉè¼ÆÓëºÏ³ÉÑо¿Ñо¿ÁìÓò£ºÐÂÒ©·Ö×ÓÉè¼ÆÓëºÏ³ÉÑо¿[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**µç×ÓÓʼþ£ºqianhai24@163.comͨ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27º£ÄÏҽѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-¸¶À¥
µ¼Ê¦ÐÕÃû£º¸¶À¥ÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º109ËùÊôԺУ£ºº£ÄÏҽѧԺËùÊôԺϵ£ºº£ÄÏҽѧԺ¸½ÊôÒ½ÔºÖ°³Æ£ºµ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÍâ¿ÆÑ§Ñо¿ÁìÓò£º¹Ç¿ÆÉúÎï²ÄÁϼ°È˹¤¹Ø½ÚÑо¿ÁìÓò£º¹Ç¿ÆÉúÎï²ÄÁϼ°È˹¤¹Ø½Ú[ÊÕÆð]¸öÈ˼òÊö:»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ²©Ê¿Ñо¿Éú±ÏÒµ£¬´ÓʹǿÆöλÔÓéÀֵǼÈë¿ÚÏÂÔØ28Äê¡£2002Äê7ÔÂÖÁ2003Äê7ÔÂÔÚÖÐɽ´ó ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖØÇì´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-¶ÊÀÎä
µ¼Ê¦ÐÕÃû£º¶ÊÀÎäÐÔ±ð£ºÈËÆøÖ¸Êý£º109ËùÊôԺУ£ºÖØÇì´óѧËùÊôԺϵ£ºÉúÎ﹤³ÌѧԺְ³Æ£ºµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖØÇì´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-µ«¾²Åà
µ¼Ê¦ÐÕÃû£ºµ«¾²ÅàÐÔ±ð£ºÅ®ÈËÆøÖ¸Êý£º109ËùÊôԺУ£ºÖØÇì´óѧËùÊôԺϵ£º¼ÆËã»úѧԺְ³Æ£º¸±½ÌÊÚµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÍ¨Ñ¶·½Ê½:°ì¹«µç»°£º**µç×ÓÓʼþ£ºdanjingpei@cqu.edu.cn¸öÈ˼òÊö:µ«¾²Åั½ÌÊÚ¡£Å®£¬1978Äê7ÔÂÉú¡£2000ÄêÔÚÖØÇì´óѧ¼ÆËã»úѧԺ»ñµÃ±¾¿ÆÑ§Î»£¬Í¬ÄêÔÚÈÕ±¾µçÆøÍ¨ÐÅ´óѧ¶Ì ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖØÇì´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-»Æ½Ë§
µ¼Ê¦ÐÕÃû£º»Æ½Ë§ÐÔ±ð£ºÈËÆøÖ¸Êý£º109ËùÊôԺУ£ºÖØÇì´óѧËùÊôԺϵ£º×Ô¶¯»¯Ñ§ÔºÖ°³Æ£ºµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27±±¾©¹¤Òµ´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÕÔÀöÇÙ
µ¼Ê¦ÐÕÃû£ºÕÔÀöÇÙÐÔ±ð£ºÈËÆøÖ¸Êý£º109ËùÊôԺУ£º±±¾©¹¤Òµ´óѧËùÊôԺϵ£ºÈËÎÄѧԺְ³Æ£º¸±½ÌÊÚµ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÉç»á¹¤×÷˶ʿ¡¢Éç»áѧÑо¿ÁìÓò£ºÇàÉÙÄêÐÄÀí×Éѯ¡¢Éç»áÐÄÀíÑо¿ÁìÓò£ºÇàÉÙÄêÐÄÀí×Éѯ¡¢Éç»áÐÄÀí[ÊÕÆð]ͨѶ·½Ê½:µç×ÓÓʼþ£ºzhaoliqin@bjut.edu.cn¸öÈ˼òÊö:ÕÔÀöÇÙ£¬Å®£¬ÐÄÀíѧ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27±±¾©¹¤Òµ´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÎãÁ¢·¼
µ¼Ê¦ÐÕÃû£ºÎãÁ¢·¼ÐÔ±ð£ºÅ®ÈËÆøÖ¸Êý£º109ËùÊôԺУ£º±±¾©¹¤Òµ´óѧËùÊôԺϵ£º¼¤¹âÔº¡¢ÐÅϢѧ²¿Ö°³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÐÅÏ¢ÓëͨÐŹ¤³Ì¡¢µç×ÓÓëͨÐŹ¤³Ì¡¢¹âѧ¹¤³Ì¡¢µç×Ó¿ÆÑ§Óë¼¼ÊõÑо¿ÁìÓò£ºÊÓÆµÄÚÈÝ·ÖÎö¼°Ó¦Ó㻸´ÔÓ±³¾°ÏµÄÈËÁ³¼ì²âÓëʶ±ð£»ÉúÎïÌØÕ÷¼ÓÃܼ°Ó¦Óã»Í¼Ïñ×ÔÊÊÓ¦Ëõ·Å¼°Ïà¹ØµÄ...[Õ¹¿ª]Ñо¿ÁìÓò£ºÊÓ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27º£ÄÏҽѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ËÕÇì½Ü
µ¼Ê¦ÐÕÃû£ºËÕÇì½ÜÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º109ËùÊôԺУ£ºº£ÄÏҽѧԺËùÊôԺϵ£ºÁÙ´²Ò½Ñ§Ö°³Æ£ºµ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÄÚ¿ÆÑ§Ñо¿ÁìÓò£ºÄÔѪ¹Ü²¡£¨ÄÔ¹£Èû£©µÄ»ù´¡£¨¶¯ÎïÄ£ÐÍ£©£¬ÁÙ´²¹æ·¶»¯ÕïÖÎÓëÔ¤·ÀÑо¿ÁìÓò£ºÄÔѪ¹Ü²¡£¨ÄÔ¹£Èû£©µÄ»ù´¡£¨¶¯ÎïÄ£ÐÍ£©£¬ÁÙ´²¹æ·¶»¯ÕïÖÎÓëÔ¤·À[ÊÕÆð]¸öÈ˼òÊö:1989.07??ÔÚÖÐɽҽ¿Æ´óѧ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27¹ãÎ÷Ãñ×å´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-À¶Æ½
µ¼Ê¦ÐÕÃû£ºÀ¶Æ½ÐÔ±ð£ºÈËÆøÖ¸Êý£º110ËùÊôԺУ£º¹ãÎ÷Ãñ×å´óѧËùÊôԺϵ£º»¯Ñ§»¯¹¤Ñ§ÔºÖ°³Æ£ºµ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÉúÎﻯ¹¤Ñо¿ÁìÓò£ºÖ÷Òª´ÓÊÂÉúÎï»ù¶àÌDzÄÁÏÖÆ±¸¼°¸ÄÐԵȷ½ÃæµÄÑо¿¹¤×÷¡£Ñо¿ÁìÓò£ºÖ÷Òª´ÓÊÂÉúÎï»ù¶àÌDzÄÁÏÖÆ±¸¼°¸ÄÐԵȷ½ÃæµÄÑо¿¹¤×÷¡£[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**µç×ÓÓʼþ£º**@qq.com¸ö ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27¹ãÎ÷Ãñ×å´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÖÜÑå
µ¼Ê¦ÐÕÃû£ºÖÜÑåÐÔ±ð£ºÈËÆøÖ¸Êý£º109ËùÊôԺУ£º¹ãÎ÷Ãñ×å´óѧËùÊôԺϵ£ºÍâ¹úÓïѧԺְ³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÓ¢Óï¿ÚÒëÑо¿ÁìÓò£ºÖйú¹ÅÊ«ÔÚ¹úÍâµÄÒë½é¡¢´«½ÌÊ¿¶ÔÖйúµä¼®µÄ·ÒëÑо¿ÁìÓò£ºÖйú¹ÅÊ«ÔÚ¹úÍâµÄÒë½é¡¢´«½ÌÊ¿¶ÔÖйúµä¼®µÄ·Òë[ÊÕÆð]¸öÈ˼òÊö:1997Ä꣬ÂÛÎÄ¡°¡¶ËÉ»¨¼ã¡·¡ªÖÒʵÓ봴еĽáºÏ¡±»ñ¹ãÎ÷ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27¹ãÎ÷Ãñ×å´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-Îé¹ã½ò
µ¼Ê¦ÐÕÃû£ºÎé¹ã½òÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º109ËùÊôԺУ£º¹ãÎ÷Ãñ×å´óѧËùÊôԺϵ£ºÌåÓýÓ뽡¿µ¿ÆÑ§Ñ§ÔºÖ°³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÃñ×崫ͳÌåÓýѧͨѶ·½Ê½:°ì¹«µç»°£º**µç×ÓÓʼþ£ºnnglin@tom.com¸öÈ˼òÊö:ÐÂÃçÌåÓý½±Ñ§½ðÐÂÃçÌåÓýÀíÊ»á**2003Äê11Ô£»¹ãÎ÷¸ßУÌåÓý¹¤×÷ÏȽø¸öÈ˹ãÎ÷ÇøÌåÓý¾Ö¡¢¹ã ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27±±¾©¹¤ÉÌ´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÑîÕêÄÍ
µ¼Ê¦ÐÕÃû£ºÑîÕêÄÍÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º112ËùÊôԺУ£º±±¾©¹¤ÉÌ´óѧËùÊôԺϵ£ºÖ°³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÑо¿ÁìÓò£ºÈéËá¾ú¡¢·¢½Í¼Á¼°ÈéÖÆÆ·Ñо¿¿ª·¢£»È鯷¼Ó¹¤Ïà¹ØÃ¸ÀàÑо¿¿ª·¢£»´«Í³ÈéÖÆÆ·ÏÖ´ú»¯¼Ó¹¤¼¼Êõ£»È鯷°²...[Õ¹¿ª]Ñо¿ÁìÓò£ºÈéËá¾ú¡¢·¢½Í¼Á¼°ÈéÖÆÆ·Ñо¿¿ª·¢£»È鯷¼Ó¹¤Ïà¹ØÃ¸ÀàÑо¿¿ª·¢£»´«Í³ÈéÖÆÆ·ÏÖ´ú»¯ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27À¼ÖÝÀí¹¤´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-¬Сƽ
µ¼Ê¦ÐÕÃû£ºÂ¬Ð¡Æ½ÐÔ±ð£ºÈËÆøÖ¸Êý£º109ËùÊôԺУ£ºÀ¼ÖÝÀí¹¤´óѧËùÊôԺϵ£ºÊ¯ÓÍ»¯¹¤Ñ§ÔºÖ°³Æ£º¸±½ÌÊÚµ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º°²È«¿ÆÑ§Ó빤³Ì¡¢¶¯Á¦¹¤³Ì¼°¹¤³ÌÈÈÎïÀí ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27
